Welcome to our dedicated page for KAMADA SEC filings (Ticker: KMDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kamada Ltd. filings document a foreign private issuer reporting on a global biopharmaceutical business focused on specialty plasma-derived therapies and marketed products for rare and serious conditions. Recent Form 6-K reports include exhibits on financial results, annual guidance, investor presentations, product-supply tenders, and FDA approval of a plasma collection center.
The filings also record ordinary-share dividend actions, withholding-tax procedures tied to Israeli tax rules, and incorporation of certain current reports by reference into Form S-8 registration statements. Kamada files as a Form 20-F issuer, with disclosures covering governance, capital-return actions, commercial portfolio performance and regulatory events affecting plasma collection and product supply.
Kamada Ltd. (KMDA) reports that it obtained a tax ruling from the Israel Tax Authority covering Israeli withholding tax on its previously announced cash dividend of $0.17 (≈NIS 0.51) per share, totaling approximately $9.8 million, expected to be paid on September 17, 2026 to shareholders of record on August 27, 2026.
Under the ruling, certain shareholders who held shares as of the record date and trade them on Nasdaq, and who reside in a tax-treaty country, may qualify for a Reduced Withholding Tax Rate on the dividend, and some Israeli corporate shareholders may qualify for an exemption, subject to conditions. Kamada appointed IBI Trust Management as Tax Agent to process applications and required forms must be provided by October 7, 2026. The company reiterates that payment of this dividend is not an indication of any future dividends.
KAMADA LTD (KMDA) reported that VP Quality Yael Brenner exercised employee stock options into ordinary shares on August 26, 2026. Three derivative transactions each covered options to purchase 10,000 ordinary shares at an exercise price of $6.25 per share, held by a trustee under the company’s 2011 Share Award Plan. According to the footnotes, a net exercise of a 10,000-share option resulted in Brenner receiving 2,776 ordinary shares while 7,224 shares underlying that option were withheld to cover the exercise price and tax withholdings, using the $8.58 closing stock price on August 26, 2026. Related non-derivative entries reflect the receipt of ordinary shares and the withholding of shares for payment of the exercise price or tax liabilities.
KAMADA LTD (KMDA) is the subject of an amended Schedule 13G filing reporting the holdings of Phoenix Financial Ltd. and its subsidiaries. Phoenix Financial reports beneficial ownership of 2,652,234.66 Ordinary Shares, representing 4.6% of Kamada’s Ordinary Shares, with shared voting and dispositive power over the same amount and no sole power.
The percentage is based on 57,681,420 Ordinary Shares outstanding as of August 16, 2026. The filing explains that various majority- or wholly-owned subsidiaries of Phoenix Financial manage these positions independently, and each disclaims beneficial ownership beyond its actual pecuniary interest. As of August 13, 2026, the holdings are spread across several Phoenix-related vehicles, and overall ownership is reported as 5 percent or less of the class.
Kamada Ltd. announced that its Board of Directors declared a cash dividend of $0.17 per share (approximately NIS 0.50), totaling about $9.8 million, on its ordinary shares. The dividend is consistent with the company’s cash dividend policy and follows record-high revenue and profitability for the first six months of 2026.
The dividend will be paid on September 17, 2026, to shareholders of record as of August 27, 2026, with tax withheld under Israeli law. Kamada highlights confidence in its business prospects and liquidity while continuing to invest in commercial growth, business development, and M&A. FIMI Opportunity Funds remains the controlling shareholder with about 38% of outstanding ordinary shares.
Kamada Ltd. reported record financial results for the three and six months ended June 30, 2026 and reaffirmed its full-year 2026 outlook. First-half revenues were $100.2 million, up from $88.8 million, driven by proprietary product sales of $83.9 million and distribution revenues of $16.2 million. Gross profit reached $41.6 million.
First-half net income was $13.4 million versus $11.3 million, with basic EPS of $0.23 versus $0.20. Adjusted EBITDA was $25.7 million, compared with $22.5 million, representing about 26% of revenues. For Q2 2026, revenues were $54.9 million and net income was $9.3 million.
As of June 30, 2026, Kamada held $70.1 million in cash, cash equivalents and short-term investments, after paying a $14.4 million special dividend in April. The company reiterated 2026 guidance of $200–$205 million in revenues and $50–$53 million in adjusted EBITDA, which it states represent 12% and 23% year-over-year growth at the midpoints and notes that first-half performance is roughly half of these targets. Strategic growth pillars include expanding sales of six FDA-approved specialty plasma products, growing its distribution and biosimilar portfolio in Israel and MENA, scaling U.S. plasma collection supported by a three-year $50 million plasma sales agreement, and pursuing M&A. Kamada also disclosed a planned transition of Chief Financial Officer Chaime Orlev, effective December 31, 2026.
Kamada Ltd granted director Karnit Goldwasser 30,000 employee stock options on August 5, 2026. The options have a convenience-converted exercise price of $7.5200 per share, vest in four equal annual installments over four years, and will be exercisable for ten years from the grant date, after which unexercised options expire. They are held indirectly by a trustee under Kamada’s 2011 Share Award Plan.
Kamada Ltd reported that director Uri Botzer received a grant of 30000.0000 Employee Stock Options to purchase Ordinary Shares at an exercise price of $7.5200 per share, translated from NIS using the Bank of Israel rate as of August 4, 2026. The options vest in four equal 25% annual installments, are exercisable for 10 years from the grant date, and any unexercised options then expire. The award is held indirectly by a trustee under the company’s 2011 Share Award Plan.
Kamada Ltd director Lilach Asher-Topilsky received a grant of 30,000 employee stock options to buy ordinary shares at an exercise price of $7.52 per share, presented in U.S. dollars based on an NIS exchange rate. The options vest in four equal annual installments over four years, are exercisable for ten years from grant, and are held indirectly by a trustee under Kamada's 2011 Share Award Plan.
Kamada Ltd director David Tsur received a grant of 30,000 Employee Stock Options, each exercisable into one Ordinary Share at an exercise price of $7.5200 per share. The options, held indirectly by a trustee under Kamada's 2011 Share Award Plan, vest in four equal annual installments over four years and are exercisable for 10 years from the grant date.
Dekel Benjamin, a director of Kamada Ltd, received a grant of 30,000 employee stock options to buy ordinary shares at an exercise price of $7.5200 per share. The options vest in four equal annual installments over four years, are exercisable for 10 years, and are held indirectly by a trustee under the company's 2011 Share Award Plan.